car-cldn18.2 t-cells

Cell therapyexperimental

Clinical trial activity

8 trials · 11 clinical orgs · 0 marketing orgs

Phase 1
6
Phase 2
1
Phase 3
0
Phase 4
0

Earliest trial started Mar 26, 2019 (NCT03874897)

Timeline

2010s

  1. Jan 1, 2019

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07266311Early Phase 1 (Phase 1)Dec 15, 2025Government of China, People's Liberation Army of China
NCT07066995Phase 1/Phase 2 (Phase 2)Apr 29, 2025Essen Biotech
NCT06946615Phase 1Apr 8, 2025Zhejiang University
NCT06353152Phase 1Nov 17, 2023Gracell Biotechnology Ltd., Peking University
NCT05952375N/AMar 1, 2023Qingdao University
NCT05620732N/AOct 1, 2022Shenzhen University
NCT05472857Phase 1Aug 8, 2022Changhai Hospital, Government of China
NCT03874897Phase 1Mar 26, 2019CARsgen Therapeutics, Ltd., Chinese Academy of Medical Sciences, Peking University
Showing 8 of 8 trials
Page 1 / 1

Organizations

Research & Development (11)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Government of ChinaGovernment2212022
Peking UniversityAcademic/Hospital2212019
CARsgen Therapeutics, Ltd.For profit1012019
Changhai HospitalAcademic/Hospital1012022
Chinese Academy of Medical SciencesAcademic/Hospital1012019
Essen BiotechFor profit1112025
Gracell Biotechnology Ltd.For profit1012023
People's Liberation Army of ChinaGovernment1012025
Qingdao UniversityAcademic/Hospital1112023
Shenzhen UniversityAcademic/Hospital1112022
Zhejiang UniversityAcademic/Hospital1112025
11 organizations
Page 1 / 1